Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants
We developed a case-case study to compare mRNA vaccine effectiveness against Delta versus Alpha coronavirus variants. We used data on 2,097 case-patients with PCR-positive severe acute respiratory syndrome coronavirus 2 infections reported in Portugal during May-July 2021. We estimated the odds of vaccine breakthrough infection in Delta-infected versus Alpha-infected patients by using conditional logistic regression adjusted for age group and sex and matched by the week of diagnosis. We compared reverse-transcription PCR cycle threshold values by vaccination status and variant as an indirect measure of viral load. We found significantly higher odds of vaccine breakthrough infection in Delta-infected patients than in Alpha-infected patients (odds ratio 1.96 [95% CI 1.22-3.14]), suggesting lower effectiveness of the mRNA vaccines in preventing infection with the Delta variant. We estimated lower mean cycle threshold values for the Delta cases (mean difference -2.10 [95% CI -2.74 to -1.47]), suggesting higher infectiousness than the Alpha variant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 28(2022), 2 vom: 07. Feb., Seite 331-337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kislaya, Irina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.01.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2802.211789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334128838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334128838 | ||
| 003 | DE-627 | ||
| 005 | 20231227130638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2802.211789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM334128838 | ||
| 035 | |a (NLM)34876242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kislaya, Irina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We developed a case-case study to compare mRNA vaccine effectiveness against Delta versus Alpha coronavirus variants. We used data on 2,097 case-patients with PCR-positive severe acute respiratory syndrome coronavirus 2 infections reported in Portugal during May-July 2021. We estimated the odds of vaccine breakthrough infection in Delta-infected versus Alpha-infected patients by using conditional logistic regression adjusted for age group and sex and matched by the week of diagnosis. We compared reverse-transcription PCR cycle threshold values by vaccination status and variant as an indirect measure of viral load. We found significantly higher odds of vaccine breakthrough infection in Delta-infected patients than in Alpha-infected patients (odds ratio 1.96 [95% CI 1.22-3.14]), suggesting lower effectiveness of the mRNA vaccines in preventing infection with the Delta variant. We estimated lower mean cycle threshold values for the Delta cases (mean difference -2.10 [95% CI -2.74 to -1.47]), suggesting higher infectiousness than the Alpha variant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alpha variant | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Delta variant | |
| 650 | 4 | |a Portugal | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a breakthrough infections | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a mRNA vaccines | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a vaccine-preventable diseases | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 700 | 1 | |a Rodrigues, Eduardo Freire |e verfasserin |4 aut | |
| 700 | 1 | |a Borges, Vítor |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, João P |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, José P |e verfasserin |4 aut | |
| 700 | 1 | |a Peralta-Santos, André |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Baltazar |e verfasserin |4 aut | |
| 700 | 0 | |a PT-COVID-19 Group |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Ausenda |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, Ana Paula |e investigator |4 oth | |
| 700 | 1 | |a Dias, Carlos Matias |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Rita |e investigator |4 oth | |
| 700 | 1 | |a Isidro, Joana |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Miguel |e investigator |4 oth | |
| 700 | 1 | |a Duarte, Sílvia |e investigator |4 oth | |
| 700 | 1 | |a Vieira, Luís |e investigator |4 oth | |
| 700 | 1 | |a Leite, Pedro Pinto |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Joana |e investigator |4 oth | |
| 700 | 1 | |a Gonçalves, António Maia |e investigator |4 oth | |
| 700 | 1 | |a Menezes, Luís |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 28(2022), 2 vom: 07. Feb., Seite 331-337 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:07 |g month:02 |g pages:331-337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2802.211789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 07 |c 02 |h 331-337 | ||